Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Early Phase 1 Interventional

RANKL Inhibition and Breast Tissue Biomarkers

ClinicalTrials.gov ID: NCT03629717

Public ClinicalTrials.gov record NCT03629717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 10:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

RANKL Inhibition and Breast Tissue Biomarkers in Premenopausal Women With Dense Breasts

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A robust knowledge of how to reduce breast density could play a key role in breast cancer prevention in premenopausal women, but viable preventative targets to reduce breast density-associated breast cancer risk are yet to be developed. The investigators propose to investigate the effect of RANKL inhibition with denosumab on breast tissue markers in high-risk premenopausal women with dense breasts. Study findings could provide robust evidence to move forward with a clinical trial targeting RANKL inhibition in premenopausal breast cancer prevention.

Study identification

NCT ID
NCT03629717
Recruitment status
Completed
Study type
Interventional
Phase
Early Phase 1
Enrollment
10 participants

Conditions and interventions

Eligibility (public fields only)

Age range
35 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2018
Primary completion
Dec 2, 2018
Completion
Dec 2, 2018
Last update posted
Oct 15, 2024

2018

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Washington University School of Medicine St Louis Missouri 63110

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03629717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 15, 2024 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03629717 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →